The overall objective of this project is to determine the cellular and molecular mechanisms which mediate the synergistic effects of retinoic acid (RA) and interferon-g (IFN-g) and sodium phenylacetate (NaPA) on the differentiation of human neuroblastoma (nb) cells. The applicants' data suggest that these compounds affect different control points in regulation of expression of the N-myc oncogene and, together, can overcome nb cell heterogeneity and resistance to differentiation in response to single agent treatment. Studies showed that IfN-g treatment and RA act on distinct regions of the N-myc promoter to decrease N-myc transcription. The first specific aim is to characterize the promoter domains and protein interactions that mediate IfN-g induced downregulation of N-myc. Using transient transfections of nb cells with N-myc promoter-CAT constructs, the precise boundaries and critical nucleotide positions within the IfN- g response element (IRE) will be determined by observing the effects of specific mutations of IRE function. Biochemical analyses using gel retardation and footprinting will be performed to correlate function of these sequences with specific DNA-protein binding. Our studies have shown that NaPa impacts on the RA pathway at the nuclear level by upregulating RARb expression through the classical RV response element RAREb. The second specific aim is to establish the mechanism of this activity. The investigator will characterize the nuclear protein(s) that are induced by NaPa to bind RAREb, assess the effects of NaPa on expression of retinoid-X receptors, and determine other possible responsive domains mediating NaPa transactivation of RAREb. The third specific aim is to evaluate the consequence of the multi-drug downregulation of N-myc expression and induction of nb differentiation in an in vivo nude mouse model. The experiments will determine whether combination treatment protocols can increase the therapeutic efficacy compared with RA alone and prevent the outgrowth of differentiation resistant populations.By understanding the relationship between RA, IFNg and NaPA in controlling nb differentiation, these studies will provide a basic framework for the expanded clinical use of retinoids in a multidrug setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043503-11
Application #
2894691
Study Section
Special Emphasis Panel (ZRG1-NEUC (02))
Program Officer
Forry-Schaudies, Suzanne L
Project Start
1986-05-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Barua, Arun B; Sidell, Neil (2004) Retinoyl beta-glucuronide: a biologically active interesting retinoid. J Nutr 134:286S-289S
Tuthill, Matthew C; Wada, Randal K; Arimoto, Jason M et al. (2003) N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab 80:272-80
Sidell, N; Pasquali, M; Malkapuram, S et al. (2003) In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells. Br J Cancer 89:412-9
Han, S; Wada, R K; Sidell, N (2001) Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res 61:3998-4002
Sawatsri, S; Samid, D; Malkapuram, S et al. (2001) Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer 93:687-92
Han, S W; Greene, M E; Pitts, J et al. (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res 7:98-104
Sidell, N; Sawatsri, S; Connor, M J et al. (2000) Pharmacokinetics of chronically administered all-trans-retinoyl-beta-glucuronide in mice. Biochim Biophys Acta 1502:264-72
Sidell, N; Chang, B; Yamashiro, J M et al. (1998) Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res 239:169-74
Connor, M J; Sidell, N (1997) Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol Chem Neuropathol 30:239-52
Wada, R K; Pai, D S; Huang, J et al. (1997) Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett 121:181-8

Showing the most recent 10 out of 33 publications